The ethics of disease-modifying drugs targeting Alzheimer disease: response to our commentators

Gustavsson, Erik; Raaschou, Pauline; Lärfars, Gerd; Sandman, Lars; Juth, Niklas

doi:10.1136/medethics-2022-108157

Cited by 2 publications

(5 citation statements)

References 4 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cognitive impairment and other dementing diseases, driven primarily by the most prevalent cause, AD, remain one of the largest global public health challenges facing health care today. Across the planet, there are now upward of 50 million people living with these conditions and the annual costs are estimated to approach US$1 trillion in 2022 19 . Together the prevalence of these conditions and the cost of illness represent a societal burden that will increase dramatically each and every decade through the century's end 19 …”

Section: Discussionmentioning

confidence: 99%

“…Across the planet, there are now upward of 50 million people living with these conditions and the annual costs are estimated to approach US$1 trillion in 2022 19 . Together the prevalence of these conditions and the cost of illness represent a societal burden that will increase dramatically each and every decade through the century's end 19 …”

Section: Discussionmentioning

confidence: 99%

“…Across the planet, there are now upward of 50 million people living with these conditions and the annual costs are estimated to approach US$1 trillion in 2022. 19 Together the prevalence of these conditions and the cost of illness represent a societal burden that will increase dramatically each and every decade through the century's end. 19 In the United States as well as the rest of the world, this societal burden represents the most important motivation for the various national dementia prevention initiatives of the last 10 years.…”

Section: Discussionmentioning

confidence: 99%

“…19 Together the prevalence of these conditions and the cost of illness represent a societal burden that will increase dramatically each and every decade through the century's end. 19 In the United States as well as the rest of the world, this societal burden represents the most important motivation for the various national dementia prevention initiatives of the last 10 years. [20][21][22][23][24] The US National Alzheimer's Project Act, the UK Prime Minister's Challenge on Dementia, the French National Dementia Strategies, the Japanese New Orange Plan, and others represent the culmination of a series of initial research planning workshops/think-tank meetings organized by groups such as PAD (20/20), [21][22][23][24] Alzheimer's Association, 25 and the Organization for Economic Cooperation and Development (OECD).…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Improving community health‐care systems’ early detection of cognitive decline and dementia

Khachaturian¹

2022

Alzheimer's & Dementia

View full text Add to dashboard Cite

Preliminary estimates suggest that current global health-care systems lack the resource capacity to provide persons with dementia timely access to diagnosis, treatment, and care. There is an increasing need to improve timely identification of individuals who will likely progress to Alzheimer's disease (AD) dementia particularly among under-represented, underserved, and vulnerable populations. The rapidly evolving area of bioinformatics of health system data and the emergence of fluid-based biomarkers for pre-symptomatic AD may provide an innovative strategic option for health system planners. A think-tank style meeting entitled "The Campaign to Prevent Alzheimer's Disease Work Group on Community-Based Detection and Assessment of Cognitive Decline" developed recommendations to guide future sustainability activities, public policy campaigns, and implementation pilots. The group identified and explored different pathways of community-based detection using electronic health records, from different international health-care systems, to detect and surveil individuals with early possible cognitive impairment. BACKGROUNDDespite enjoying the current longevity revolution, global society is now on the precipice of a new form of political and economic instability. The crisis is composed of escalating costs for the diagnosis, assessment, treatment, and care of many age-associated disorders that affect memory, movement, and mood. Further, this burden is magnified doubly by the dementia and SARS-CoV-2 pandemics stressing already existing and inadequate health-care service delivery programs for older adults. 1 Dementing illnesses, driven primarily by the most prevalent cause, Alzheimer's disease (AD), remain one of the largest global public health challenges facing health care today. There are now upward of 50 million people living with dementia and the global cost of dementia was estimated to be US$1.3 trillion in 2019. 2 Most of these costs occur in high income countries (HICs) although most people with dementia live in low/middle income countries (LMICs). If incident dementia predictions continue over the next 10 years, the global costs of dementia will increase to a projected US$1.7 trillion by 2030. 2 These global estimates increase to US$2.8 trillion by 2030 with corrections for increases in care costs. 2The global societal dementia burden is the key motivation for the various national and international dementia prevention initiatives over the past decade. The earliest efforts examined the issue of how to accelerate pharmaceutical intervention development. Next, the research community's focus shifted to explore opportunities to develop accurate assessment technologies in asymptomatic/early impairment individuals and to evaluate the effectiveness of non-pharmacological/lifestyle interventions. Today, there is a growing level of interest in identifying key public health opportunities that lessen the burden of disability due to dementia and its comorbid conditions at the community level. [3][4][5] The early and accurate asses...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Improving community health‐care systems’ early detection of cognitive decline and dementia

Khachaturian¹

2022

Alzheimer's & Dementia

View full text Add to dashboard Cite

show abstract

“…During the initial therapeutic approach, acetylcholinesterase inhibitors, monoclonal antibodies, and NMDA receptor antagonists are administered. In more advanced stages of the disease, a combination therapy incorporating antidepressants, anxiolytics, and antipsychotics is usually chosen (Gustavsson et al, 2022;Cammisuli et al, 2022). These therapies often lead to adverse effects such as confusion, edema, and microhemorrhages, in addition to showing reduced efficacy (Huang et al, 2020;Alhazmi & Albratty, 2022).…”

Section: Introductionmentioning

confidence: 99%

Phenols as an alternative, neuroprotective, and preventive strategy for Alzheimer's disease: (mini-review and bibliometric analysis)

Iñiguez-Luna,

Suárez-Medellín,

Vidal-Limon

2023

View full text Add to dashboard Cite

Objective: This study aimed to perform a bibliometric review focused on secondary metabolites of phenolic origin in the context of Alzheimer's disease. Analyzing the research trend in this field during the last two decades, highlighting the chemical-computational (in silico) perspective Design/methodology/approach: Publications from the last two decades (2001-2023) were examined using the academic search engine Dimensions. The focus of our analysis was on identifying co-occurrence networks of terms present in the titles and abstracts of these publications, setting a minimum threshold of 100 co-occurrences for inclusion in the study (VOSviewer v. 1.6.19,2023). Results: The literature consulted suggests phenolic compounds as metabolites with preventive capacity, derived from their antioxidant, anti-inflammatory, and neuroprotective properties. Limitations on study/implications: However, it is essential to highlight the limitations observed in each area so that an integral vision is encouraged in future research. Findings/conclusions: The integration of epidemiological studies, in vitro investigations, in silico análisis, and in vivo experiments will advance the development of therapeutic strategies based on phenolic compounds for the care of multifactorial Alzheimer's disease.

show abstract

The ethics of disease-modifying drugs targeting Alzheimer disease: response to our commentators

Cited by 2 publications

References 4 publications

Improving community health‐care systems’ early detection of cognitive decline and dementia

Improving community health‐care systems’ early detection of cognitive decline and dementia

Phenols as an alternative, neuroprotective, and preventive strategy for Alzheimer's disease: (mini-review and bibliometric analysis)

Contact Info

Product

Resources

About